脂蛋白(a)作为药物治疗靶点:前提、前景与展望
综述指出Lp(a)是动脉粥样硬化性心血管病的独立危险因素,具有促炎和促血栓机制,同等摩尔浓度下致动脉粥样硬化能力约为LDL的5至6倍;因主要受遗传决定,一生一次检测即可识别升高者;孟德尔随机化研究和LDL-C降低药物试验的事后分析支持Lp(a)浓度与心血管结局的因果关系,多种Lp(a)降低药物处于不同临床研究阶段,正在进行的3期试验将进一步阐明长期降低Lp(a)的心血管获益。
要点
- Lp(a)是ASCVD独立危险因素,同等摩尔浓度下致动脉粥样硬化能力约为LDL的5至6倍。
- Lp(a)主要受遗传决定,一生一次检测即可识别水平升高者。
- 孟德尔随机化研究与降LDL-C试验事后分析支持Lp(a)与心血管结局的因果关系。
核心结论
- Lp(a)是动脉粥样硬化性心血管病的独立危险因素,治疗性降低Lp(a)预期有助于降低心血管风险。
研究设计与样本
- 综述,总结Lp(a)的致病机制、遗传决定因素、因果证据及多种在研Lp(a)降低药物的临床研究进展。
主要发现
- 同等摩尔浓度下,Lp(a)致动脉粥样硬化能力约为LDL的5至6倍。
- Lp(a)可进入血管壁,导致氧化磷脂在动脉内膜积聚,启动斑块炎症并触发血管病变进展。
- Lp(a)可能通过apoA与血小板PAR-1受体相互作用及竞争性抑制纤溶酶原导致动脉血栓形成。
- 孟德尔随机化研究和LDL胆固醇降低药物随机试验的事后分析显示Lp(a)浓度与心血管结局存在因果关联。
- 单克隆抗体、小干扰RNA、反义寡核苷酸、小分子及基因编辑化合物等多种Lp(a)降低药物处于不同临床研究阶段。
临床怎么用
- 因Lp(a)主要受遗传决定,一生一次检测即可识别水平升高的患者。
- 增加Lp(a)检测和治疗有望在人群层面识别高危个体并预防大量心血管事件。
- 正在进行的3期试验将进一步阐明长期降低Lp(a)的心血管获益,为靶向干预提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proinflammatory and prothrombotic mechanisms contributing to its atherogenicity. On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL (low-density lipoprotein). Lp(a) can enter the vessel wall, leading to the accumulation of oxidized phospholipids in the arterial intima, which are crucial for initiating plaque inflammation and triggering vascular disease progression. In addition, Lp(a) may cause atherothrombosis through interactions between apoA (apolipoprotein A) and the platelet PAR-1 (protease-activated receptor 1) receptor, as well as competitive inhibition of plasminogen. Because Lp(a) is mostly determined on genetic bases, a 1-time assessment in a lifetime can suffice to identify patients with elevated levels. Mendelian randomization studies and post hoc analyses of randomized trials of LDL cholesterol-lowering drugs showed a causal link between Lp(a) concentrations and cardiovascular outcomes, with therapeutic reduction of Lp(a) expected to contribute to estimated cardiovascular risk mitigation. Many Lp(a)-lowering drugs, including monoclonal antibodies, small interfering ribonucleic acids, antisense oligonucleotides, small molecules, and gene editing compounds, are at different stages of clinical investigation and show promise for clinical use. In particular, increased Lp(a) testing and treatment are expected to have a substantial impact at the population level, enabling the identification of high-risk individuals and the subsequent prevention of a large number of cardiovascular events. Ongoing phase 3 trials will further elucidate the cardiovascular benefits of Lp(a) reduction over the long term, offering potential avenues for targeted interventions and improved cardiovascular outcomes.
引用
- Greco A, Finocchiaro S, Spagnolo M, et al. Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects. Circulation. 2025. PMID: 39928714. doi:10.1161/CIRCULATIONAHA.124.069210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。